Comment on ‘short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis’
Restricted accessLetterFirst published online October, 2025
Comment on ‘short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis’
CarolusBDequirezPLOlivierL, et alShort- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis. Mult Scler2025; 31(4): 489–496.
2.
De RidderDVan Der AaFDebruyneJ, et alConsensus guidelines on the neurologist’s role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis. Clin Neurol Neurosurg2013; 115(10): 2033–2040.
3.
PericoliniMMigetGHentzenC, et alCortical, spinal, sacral, and peripheral neuromodulations as therapeutic approaches for the treatment of lower urinary tract symptoms in multiple sclerosis patients: A review. Neuromodulation2022; 25(8): 1065–1075.
4.
KobberøHKrhutJZvaraP, et alSacral neuromodulation for neurogenic lower urinary tract, bowel and sexual dysfunction in patients with multiple sclerosis: A pilot trial. Neurourol Urodyn2025; 44: 1109–1119.
5.
KendallHJKnopsAGerlachO, et alSacral neuromodulation in multiple sclerosis: The NEMISIS Study. Eur Urol Focus. Epub ahead of print 3 March 2025. DOI: 10.1016/j.euf.2025.02.009.
